Last reviewed · How we verify
High dose ultra short Primaquine
High-dose ultra-short primaquine rapidly eliminates malaria parasites, particularly gametocytes, to prevent transmission and treat infection.
High-dose ultra-short primaquine rapidly eliminates malaria parasites, particularly gametocytes, to prevent transmission and treat infection. Used for Malaria treatment and transmission prevention, Plasmodium vivax and Plasmodium ovale hypnozoite elimination.
At a glance
| Generic name | High dose ultra short Primaquine |
|---|---|
| Sponsor | Menzies School of Health Research |
| Drug class | 8-aminoquinoline antimalarial |
| Target | Malaria parasite (Plasmodium spp.) — mechanism involves oxidative stress generation |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Primaquine is an 8-aminoquinoline antimalarial that works by generating reactive oxygen species within malaria parasites, causing oxidative damage to parasite DNA and cellular structures. The high-dose ultra-short regimen aims to achieve rapid parasite clearance and gametocyte elimination while minimizing treatment duration, thereby reducing transmission potential and improving patient compliance.
Approved indications
- Malaria treatment and transmission prevention
- Plasmodium vivax and Plasmodium ovale hypnozoite elimination
Common side effects
- Hemolysis (in G6PD-deficient patients)
- Nausea and vomiting
- Abdominal pain
- Headache
- Methemoglobinemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- High dose ultra short Primaquine CI brief — competitive landscape report
- High dose ultra short Primaquine updates RSS · CI watch RSS
- Menzies School of Health Research portfolio CI